



Keytruda® (pembrolizumab) – Indication withdrawal

- On July 1, 2021, Merck announced that the company plans to voluntarily withdraw the accelerated approval indication for Keytruda (pembrolizumab) for the treatment of patients with:
 - Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [combined positive score (CPS ≥ 1)] as determined by a FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, human epidermal growth factor receptor 2 (HER2)/neu-targeted therapy.
- The decision was made in consultation with the FDA following the April Oncologic Drugs Advisory Committee evaluation of this third-line gastric cancer indication for Keytruda as a monotherapy because it failed to meet its post-marketing requirement of demonstrating an overall survival benefit in a Phase 3 study.
 - As agreed with the FDA, Merck will initiate the withdrawal in 6 months.
- Patients being treated with Keytruda for metastatic gastric cancer in the third- or further-line setting should discuss their care with their health care provider.
- This decision does not affect other indications for Keytruda, including its other uses in gastric cancer.
 - Refer to the Keytruda drug label for information regarding Keytruda's other FDA approved indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.